Skip to main content
Article thumbnail
Location of Repository

Low Enzymatic Activity Haplotypes of the Human Catechol-O-Methyltransferase Gene: Enrichment for Marker SNPs

By Andrea G. Nackley, Svetlana A. Shabalina, Jason E. Lambert, Mathew S. Conrad, Dustin G. Gibson, Alexey N. Spiridonov, Sarah K. Satterfield and Luda Diatchenko


Catechol-O-methyltransferase (COMT) is an enzyme that plays a key role in the modulation of catechol-dependent functions such as cognition, cardiovascular function, and pain processing. Three common haplotypes of the human COMT gene, divergent in two synonymous and one nonsynonymous (val158met) position, designated as low (LPS), average (APS), and high pain sensitive (HPS), are associated with experimental pain sensitivity and risk of developing chronic musculoskeletal pain conditions. APS and HPS haplotypes produce significant functional effects, coding for 3- and 20-fold reductions in COMT enzymatic activity, respectively. In the present study, we investigated whether additional minor single nucleotide polymorphisms (SNPs), accruing in 1 to 5% of the population, situated in the COMT transcript region contribute to haplotype-dependent enzymatic activity. Computer analysis of COMT ESTs showed that one synonymous minor SNP (rs769224) is linked to the APS haplotype and three minor SNPs (two synonymous: rs6267, rs740602 and one nonsynonymous: rs8192488) are linked to the HPS haplotype. Results from in silico and in vitro experiments revealed that inclusion of allelic variants of these minor SNPs in APS or HPS haplotypes did not modify COMT function at the level of mRNA folding, RNA transcription, protein translation, or enzymatic activity. These data suggest that neutral variants are carried with APS and HPS haplotypes, while the high activity LPS haplotype displays less linked variation. Thus, both minor synonymous and nonsynonymous SNPs in the coding region are markers of functional APS and HPS haplotypes rather than independent contributors to COMT activity

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.
    2. (2003). A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain.
    3. (2002). A highly significant association between a COMT haplotype and schizophrenia.
    4. (2006). A periodic pattern of mRNA secondary structure created by the genetic code.
    5. (2004). Alcoholism: genes and mechanisms.
    6. (1997). An association between the allele coding for a low activity variant of catechol-Omethyltransferase and the risk for breast cancer.
    7. (2006). Analysis of internal loops within the RNA secondary structure in almost quadratic time.
    8. (2002). Assay of catechol-Omethyltransferase activity in human erythrocytes using norepinephrine as a natural substrate.
    9. (2008). Association between a common haplotype in the COMT gene region and psychiatricdisordersinindividualswith22q11.2DS.IntJNeuropsychopharmacol 11:
    10. (2004). Association between catechol-O-methyltransferase and phobic anxiety.
    11. (2002). Association between the COMT locus and obsessive-compulsive disorder in females but not males.
    12. (2005). Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans.
    13. (2001). Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients.
    14. (2007). Association of genetic polymorphisms of ACADSB and COMT with human hypertension.
    15. (2004). Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women.
    16. (2007). Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia.
    17. (2006). Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli.
    18. (1997). Catechol-O-methyltransferase genotype and susceptibility to Parkinson’s disease in Japan. Short communication.
    19. (2006). Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
    20. (2003). Catecholamines and stress.
    21. (2007). CatecholO-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors.
    22. (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes.
    23. (1991). Cloning and characterization of human placental catechol-O-methyltransferase cDNA.
    24. (2004). COMT haplotypes suggest P2 promoter region relevance for schizophrenia.
    25. (2003). COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.
    26. (2004). Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 59 nuclease assay.
    27. (2002). Dobzhansky-Muller incompatibilities in protein evolution.
    28. (1976). Erythrocyte catechol-O-methyltransferase activity in facial pain patients.
    29. (1999). Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure.
    30. (2003). Family-based and casecontrol association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism.
    31. (2004). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.
    32. (2001). Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutants G185C and R202C by a second site suppressor mutation.
    33. (2005). Genetic basis for individual variations in pain perception and the development of a chronic pain condition.
    34. (1998). Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk.
    35. (1997). Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder.
    36. (2000). Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia.
    37. (2008). Haplotype associations with quantitative traits in the presence of complex multilocus and heterogeneous effects. Genet Epidemiol.
    38. (2001). Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance.
    39. (1997). High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease.
    40. (2006). Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.
    41. (2004). Increased systemic catecholamines in complex regional pain syndrome and relationship to psychological factors: a pilot study. Anesth Analg 99: 1478–1485. table of contents.
    42. (1991). Inferring the evolutionary histories of the Adh and Adh-dup loci in Drosophila melanogaster from patterns of polymorphism and divergence.
    43. (2002). Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561CRT) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk.
    44. (1993). Intermolecular mRNA-rRNA hybridization and the distribution of potential interaction regions in murine 18S rRNA.
    45. (1999). Intragenic suppression of an active site mutation in the human apurinic/apyrimidinic endonuclease.
    46. (2007). Is COMT a susceptibility gene for schizophrenia?
    47. (2001). Issues concerning association studies for fine mapping a susceptibility gene for a complex disease.
    48. (1995). Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
    49. (1995). Maintenance of pre-mRNA secondary structure by epistatic selection.
    50. (1998). Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study.
    51. (2004). Mechanisms and convergence of compensatory evolution in mammalian mitochondrial tRNAs.
    52. (2003). Mfold web server for nucleic acid folding and hybridization prediction.
    53. (2006). Molecular genetics of bipolar disorder.
    54. (2008). New functional single nucleotide polymorphism (Ala72Ser) in the COMT gene is associated with aggressive behavior in male schizophrenia.
    55. (2002). On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis.
    56. (2008). Orthodontic Treatment, Genetic Factors and Risk of Temporomandibular Disorder.
    57. (1994). Polymorphism and divergence at the prune locus in Drosophila melanogaster and D. simulans.
    58. (2008). Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia.
    59. (2007). Recent and ongoing selection in the human genome.
    60. (1995). Role of the sympathetic nervous system in acute pain and inflammation.
    61. (1995). SAMSON: a software package for the biopolymer primary structure analysis.
    62. (2006). Scan of human genome reveals no new Loci under ancient balancing selection.
    63. (1996). Second-site suppression of regulatory phosphorylation in Escherichia coli isocitrate dehydrogenase.
    64. (2003). Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.
    65. (1993). Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme.
    66. (2003). Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.
    67. (2004). The association between panic disorder and the L/L genotype of catechol-O-methyltransferase.
    68. (1985). The role of compensatory neutral mutations in molecular evolution.
    69. (2005). The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.
    70. (1995). Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.
    71. (2006). Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder.
    72. (2008). Val/Met Polymorphism of the COMT Gene Moderates the Association Between Job Strain and Early Atherosclerosis in Young Men.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.